Novo Suspended by UK Pharma Group Over Weight Drug Marketing.

Novo failed to make clear its involvement in a training on weight-loss drugs that was offered to pharmacists on LinkedIn, according to the Association of the British Pharmaceutical Industry. (Bloomberg) -- The UK pharmaceutical industry association suspended Novo Nordisk A/S for two years over its marketing of a weight-loss drug, saying the company breached the industry's code of conduct. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)